Fosun Pharma Acquires World Leading Laser Medical and Aesthetic Device Manufacturer, Speeding Up Internationalization

HONG KONG, April 28, 2013 /PRNewswire/ -- Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or the "Company"; stock code: 600196-SH, 02196-HK; and, together with its subsidiaries, the "Group"), a leading healthcare company in the PRC, announced the joint acquisition with Pramerica-Fosun Fund and spending not exceeding US$240 million to acquire 95.6% shareholding of Alma Lasers Ltd. ("Alma Lasers") in Israel. The realization of its first internationalized merger and acquisition is a significant step forward toward internationalization for Fosun Pharma after the completion of its H Shares offering and the opening up of the international capital channel.

Alma Lasers is an internationally well-known manufacturer of laser, light-based, radiofrequency and ultrasound products with integrated product portfolios for aesthetic and medical applications, and businesses located around the world. With its world-leading core research and development (R&D) capabilities in the medical and aesthetic device manufacturing field, Alma Lasers has established a leading global brand and recorded rapid growth in its performance. In the past decade, Alma Lasers has performed outstandingly.  According to the independent third party's report, Alma Laser captures a 15% share of the global market for high-end aesthetic devices with annual turnover near US$100 million.

There are three key sectors in the laser medical and aesthetic device industry, namely, high-end aesthetic devices, surgical devices and the devices for domestic use market. Alma Lasers is one of the leaders in the high-end aesthetic device market and has gained a foothold in the surgical device market at the end of 2012. At the same time, Alma Lasers has principally completed the R&D stage for its devices for domestic use.

Doctor Ziv Karni, the Chief Executive Officer of Alma, is fully confident with this cooperation with Fosun Pharma, saying, "Alman team is glad to become one of the members of Fosun Pharma. Fosun Pharma's previous successful experience in the merger and acquisition and the medical healthcare as well as the medical aesthetic device fields, these strategic development focus will become Alman's excellent platform in Asia as well as in the World's business development. We do look forward to cooperating with Fosun Pharma's management team and benefit from their professional experiences."

Globally, there is still room for growth in the aesthetic medical equipment market. Alma Lasers began doing business in China in 2003, and has already become the market leader in the exclusive field of medical cosmetic lasers. By far, China is one of the biggest markets for Alma Lasers.

Mr. Chen Qiyu, Chairman of Fosun Pharma, said, "We are confident in the growth of the global aesthetics industry, especially in China, Brazil, Russia and India. This represents a huge development space in developing countries. We will continue to support the global business development of Alma Lasers." Fosun Pharma will establish Alma Lasers as a management platform for the R&D, manufacturing and sales of high-end medical devices, providing an internationalized development path for the company.

About Alma Lasers Ltd.

Founded in 1999, Alma Lasers is a renowned global manufacturer of laser, light-based, radiofrequency and ultrasound devices for aesthetic and medical applications, with a fully integrated product supply chain. The company's R&D headquarters is situated in Caesarea, Israel and its global support centre is located in Chicago, USA. With its excellent performance over the past decade, Alma Lasers has become the leading enterprise in the industry with annual revenue of about US$100 million. According to a Harris Williams report, Alma Lasers has a 15% market share in the global high-end medical and beauty laser products industry. Alma Lasers entered the China market in 2003 and has since become the leader in this industry.

About the Founder of Alma Lasers Ltd.

Ziv Karni, the founder of Alma Lasers, is the chief executive officer of the company. Dr. Ziv has been working in the R&D of medical lasers for more than 20 years and is the patent explorer and owner of a number of medical laser technologies. Dr. Ziv is one of the pioneers in introducing lasers into the medical field and promoting the tight collaboration of laser technology and clinical application. As of the end of 2012, the near 40-strong R&D team that he leads has 74 patents, and applications for an additional 23 patents.

For more information, please refer to http://www.almalasers.com/int/.

About Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Fosun Pharma is a leading healthcare company in the PRC. The Group was established in 1994 with headquarters located in Shanghai, and was listed on the Shanghai Stock Exchange in 1998. In October 2012, though the international financial environment was unfavorable, the Company successfully completed offering and listing H shares in Hong Kong. As a result, the Company has listings in both the A share market and the H share market. The Group has achieved significant results with strengthened corporate governance and investor relationship management. In addition to the SSE 180 Index, CSI 300 Index, SSE Dividend Index and SSE Corporate Governance Index, Fosun Pharma is also included in the SSE Private Enterprise 50 Index and SSE Social Responsibility Index. According to IMS Health Incorporated ("IMS"), the Group was one of the top five domestic pharmaceutical companies in the PRC by revenue in the pharmaceutical manufacturing segment in 2011. The Group's business operations strategically cover multiple important segments in the healthcare industry value chain, with business segments including pharmaceutical manufacturing, pharmaceutical distribution and retail, healthcare services and diagnostic products and medical devices.

Additional information about Fosun Pharma is available at http://www.fosunpharma.com.

Issued by Porda Havas International Finance Communications Group for and on behalf of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. For further information, please contact:

Porda Havas International Finance Communications Group